CSPG4, a transmembrane proteoglycan, had been originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells [45], and during the last decades, several works proposed it as a new therapeutic target for immune therapy in different cancers [25], including monoclonal antibodies in triple-negative breast cancer [46] and melanoma [47], antibody-drug conjugate in melanoma [48], and CAR-T cells in many cancers [49]. Here, CSPG4 is linked to melanoma.